This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Kahalalide F

Medimetriks Pharmaceuticals, Inc.

Drug Names(s): Kahalalide F

Description: Kahalalide F is a synthetic depsipeptide that was originally extracted from the Hawaiian sea slug Elysia rufescens. Although the exact mechanism of action is unknown, researchers believe that the compound disrupts lysosome membranes, thereby initiating apoptosis.

Deal Structure: In June 2009, PharmaMar and Medimetriksannounced a license agreement coveringKahalalide F and two of its analogs for uses outside of Oncology and Neurology. Medimetriks received a worldwide license to Kahalalide F and two of itsanalogs for uses outside of Oncology and Neurology, with the right to sublicense.PharmaMar will initially provide the Kahalalide F drug substance to Medimetriks and retainall rights to Kahalalide F and the two analogs for the treatment of cancer and centralnervous systems disorders. All subsequent preclinical and clinical development as well as commercialization will befinanced by Medimetriks, its sublicensee(s), or both these parties. PharmaMar shall receivedevelopment milestone payments and royalties on worldwide sales of Kahalalide F and its twoanalogs as well as part of any additional income, such as upfront or milestone payments,that Medimetriks may receive from its sublicensees.

Partners: PharmaMar

Kahalalide F News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug